Back to top
more

Owens & Minor (OMI)

(Real Time Quote from BATS)

$6.44 USD

6.44
498,199

-0.07 (-1.08%)

Updated Aug 6, 2025 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks News

Zacks Equity Research

Top Ranked Growth Stocks to Buy for March 22nd

UEIC, HRI, OMI, and REPYY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 22, 2021

Zacks Equity Research

Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable

Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.

Zacks Equity Research

NuVasive (NUVA) Hits a New 52-Week High: What's Driving It?

NuVasive (NUVA) is optimistic about its strong international performance and a huge growth potential in the spine market.

Zacks Equity Research

Penumbra (PEN) Launches INDIGO System Lightning 7 in US

Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.

    Zacks Equity Research

    Zacks.com featured highlights include: Vishay Intertechnology, PVH Corp, Owens & Minor and Sanmina Corp

    Zacks.com featured highlights include: Vishay Intertechnology, PVH Corp, Owens & Minor and Sanmina Corp

    Kinjel Shah headshot

    Buy These 7 Stocks With Low P/B Ratio to Boost Returns

    P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects. PVH Corp. (PVH), Honda Motor (HMC), Owens & Minor (OMI), ArcelorMittal (MT), Hologic (HOLX), ASE Technology Holding (ASX) and Goldman Sachs (GS) are good stocks to add.

    Zacks Equity Research

    Cardiovascular Systems' (CSII) WIRION Cures 1st U.S Patient

    Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.

    Sumit Singh headshot

    Create a Standout Portfolio With These 4 Low P/CF Stocks

    Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Vishay Intertechnology (VSH), PVH Corp. (PVH), Owens & Minor (OMI) and Sanmina Corporation (SANM) boast low P/CF ratio.

    Zacks Equity Research

    Top Ranked Growth Stocks to Buy for March 17th

    Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 17th

    Zacks Equity Research

    Owens & Minor (OMI) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, Owens & Minor (OMI) closed at $35.98, marking a -1.72% move from the previous day.

    Zacks Equity Research

    Top Ranked Growth Stocks to Buy for March 15th

    Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 15th

    Nilanjan Banerjee headshot

    Buy These 5 Low-Beta Stocks & Combat the Choppy Market

    Low-beta stocks may be able to help sail through the choppy market conditions.

    Zacks Equity Research

    Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

    Investors remain optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies and robust testing portfolio.

    Zacks Equity Research

    Earnings Estimates Rising for Owens & Minor (OMI): Will It Gain?

    Owens & Minor (OMI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    Zacks Equity Research

    Top Ranked Growth Stocks to Buy for March 9th

    Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 9th

    Zacks Equity Research

    Abbott's (ABT) Diagnostics Arm to Gain From New & Updated EUAs

    Abbott's (ABT) Alinity m SARS-CoV-2 test set to detect COVID-19 in individuals who do not have symptoms.

    Zacks Equity Research

    Boston Scientific (BSX) Buys Lumenis to Expand in Urology

    The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.

    Zacks Equity Research

    Abbott (ABT) Gets Canadian Nod for FreeStyle Libre Expanded Use

    Abbott's (ABT) FreeStyle Libre is the only glucose sensing technology available in Canada to remotely monitor glucose status in an expectant mother to reduce exposure to COVID-19.

    Zacks Equity Research

    Top Ranked Growth Stocks to Buy for March 3rd

    Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 3rd

    Zacks Equity Research

    Zacks.com featured highlights include: Owens & Minor, Sturm Ruger & Company, Natus Medical, Penumbra and Toyota Motor

    Zacks.com featured highlights include: Owens & Minor, Sturm Ruger & Company, Natus Medical, Penumbra and Toyota Motor

    Zacks Equity Research

    Medtronic's (MDT) Market Share Grows Amid COVID-19 Woes

    In Coronary, the ongoing issue related to the China drug-eluting stent national tender, Medtronic (MDT) is currently winning share globally.

    Zacks Equity Research

    Thermo Fisher (TMO) Buys Mesa Biotech, Grows in Point of Care

    Mesa Biotech's point-of-care platform is likely to help Thermo Fisher (TMO) rapidly scale up manufacturing volume amid the pandemic.

    Zacks Equity Research

    Top Ranked Growth Stocks to Buy for March 1st

    Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 1st

    Zacks Equity Research

    New Strong Buy Stocks for March 1st

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

    Nilanjan Banerjee headshot

    Buy These 5 Low-Beta Stocks to Beat the Choppy Market

    To combat the choppy market conditions, it is of utmost importance to create a portfolio of low-beta stocks.